Abstract
Extracellular vesicles (EVs) are sophisticated and sensitive messengers released by cells to communicate with and influence distant and neighboring cells via selective transfer of bioactive content, including protein lipids and nucleic acids. EVs have therefore attracted broad interest as new and refined potential therapeutic systems in many diseases, including cancer, due to their low immunogenicity, non-toxicity, and elevated bioavailability. They might serve as safe and effective vehicles for the transport of therapeutic molecules to specific tissues and cells. In this review, we focus on EVs as a vehicle for gene therapy in cancer. We describe recent developments in EV engineering to achieve efficient intracellular delivery of cancer therapeutics and avoid off-target effects, to provide an overview of the potential applications of EV-mediated gene therapy and the most promising biomedical advances.
Highlights
Extracellular vesicles (EVs) are nanoscale particles released by producing cells in the extracellular environment to interact with and act on distant and neighboring cells
We focus on EVs as a vehicle for gene therapy in cancer
We describe the potential use of EVs as a tool for therapeutic nucleic acid delivery to target cells, to improve treatment efficacy and avoid side effects
Summary
Extracellular vesicles (EVs) are nanoscale particles released by producing cells in the extracellular environment to interact with and act on distant and neighboring cells. The MSC-EVs are widely used as therapeutic agents for different immunological disorders [26] and their use has shown incredibly promising results in clinical trials on severe forms of graft-versus-host disease (GvHD; Grade II–IV) [27]; chronic kidney diseases [28]; and Type I Diabetes Mellitus (T1DM) [29]. Another example of how EVs are able to negatively regulate immunoresponse is given by immature dendritic cell (DC)-derived EVs devoid of immunostimulatory molecules (MHC-I and -II) [30] and carrying co-regulatory proteins that suppress immune reactions. Immature DCs were described as a major source of EVs [57] and as innovative cell-free vaccines, reverting cancer immune escape [58,59,60]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
